Active Ingredient History
Dapagliflozin (trade name Farxiga in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, developed by Bristol-Myers Squibb in partnership with AstraZeneca. Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Kidney Injury (Phase 4)
Aging (Phase 1/Phase 2)
Albuminuria (Phase 2)
Alzheimer Disease (Phase 1/Phase 2)
Anemia (Phase 4)
Angina, Unstable (Phase 3)
Aortic Valve Disease (Phase 4)
Aortic Valve Stenosis (Phase 4)
Ascites (Phase 2)
Atrial Fibrillation (Phase 4)
Biomarkers (Phase 2/Phase 3)
Blood Glucose (Phase 4)
Blood Platelet Disorders (Phase 2/Phase 3)
Bone Diseases, Metabolic (Phase 4)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Cardiac Catheterization (Phase 4)
Cardiomegaly (Phase 2)
Cardiomyopathies (Phase 2)
Cardiomyopathy, Dilated (Phase 3)
Cardio-Renal Syndrome (Phase 2)
Cardiovascular Diseases (Phase 4)
Carotid Artery Diseases (Phase 4)
Catheter Ablation (Phase 2/Phase 3)
Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2/Phase 3)
Cognition Disorders (Phase 3)
Cognitive Dysfunction (Phase 2/Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
COVID-19 (Phase 3)
Critical Illness (Phase 3)
Cystinuria (Phase 2)
Death (Phase 3)
Dementia, Vascular (Phase 2/Phase 3)
Depressive Disorder (Phase 2)
Diabetes Complications (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Ketoacidosis (Phase 1)
Diabetic Nephropathies (Phase 4)
Diabetic Neuropathies (Phase 4)
Diabetic Retinopathy (Phase 3)
Diet, Ketogenic (Phase 4)
Drug Evaluation (Phase 4)
Drugs, Investigational (Phase 1)
Endocrine System Diseases (Phase 3)
Endomyocardial Fibrosis (Phase 4)
Endothelial Cells (Phase 4)
Endothelium (Phase 4)
Essential Hypertension (Phase 3)
Exercise (Phase 2)
Fabry Disease (Phase 2)
Fatty Liver (Phase 4)
Fibrosis (Phase 2)
Glomerulosclerosis, Focal Segmental (Phase 4)
Glucose Intolerance (Phase 4)
Glucose Metabolism Disorders (Phase 4)
Glucose Tolerance Test (Phase 3)
Glycemic Control (Phase 4)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 2)
Heart Disease Risk Factors (Phase 2)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 4)
Heart Ventricles (Phase 4)
Hypercholesterolemia (Phase 4)
Hyperglycemia (Phase 4)
Hyperinsulinism (Phase 1)
Hyperoxaluria (Phase 4)
Hypertension (Phase 4)
Hypertension, Pulmonary (Phase 2)
Hypertrophy, Left Ventricular (Phase 4)
Hyperuricemia (Phase 2)
Hypoglycemia (Phase 4)
Hypotension (Phase 4)
Hypoxia (Phase 4)
Inflammation (Phase 2)
Inflammatory Bowel Diseases (Phase 2/Phase 3)
Insulin (Phase 4)
Insulin Resistance (Phase 3)
Ischemic Stroke (Phase 2/Phase 3)
Ketosis (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Function Tests (Phase 4)
Kidney Transplantation (Phase 4)
Liver Cirrhosis (Phase 2)
Lung Diseases (Early Phase 1)
Lupus Erythematosus, Systemic (Phase 4)
Lupus Nephritis (Phase 4)
Metabolic Diseases (Phase 3)
Metabolic Syndrome (Phase 4)
Metabolism (Phase 4)
Mitochondrial Diseases (Phase 4)
Mitral Valve (Phase 4)
Mitral Valve Stenosis (Phase 3)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Myocardium (Phase 4)
Nephrotic Syndrome (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 3)
Obesity (Phase 4)
Obesity, Morbid (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 1)
Percutaneous Coronary Intervention (Phase 4)
Pharmacokinetics (Phase 2/Phase 3)
Polycystic Ovary Syndrome (Phase 3)
Prediabetic State (Phase 4)
Prehypertension (Phase 4)
Prostatic Neoplasms (Phase 1)
Proteinuria (Phase 4)
Pulmonary Arterial Hypertension (Phase 2)
Renal Dialysis (Phase 2)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Reperfusion Injury (Phase 1)
Rheumatic Heart Disease (Phase 3)
Risk Reduction Behavior (Phase 3)
Sepsis (Phase 3)
Sleep Apnea Syndromes (Phase 2)
Sodium-Glucose Transporter 2 Inhibitors (Phase 4)
Sports Medicine (Early Phase 1)
ST Elevation Myocardial Infarction (Phase 3)
Stroke (Phase 2)
Therapeutic Equivalency (Phase 1)
Thoracic Surgery (Phase 4)
Urolithiasis (Phase 4)
Vascular Diseases (Phase 4)
Ventricular Dysfunction, Left (Phase 3)
Ventricular Remodeling (Phase 4)
Weight Loss (Phase 2/Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue